How to buy C4 Therapeutics stock

C4 Therapeutics, Inc is an other business based in the US. C4 Therapeutics shares (CCCC) are listed on the NASDAQ and all prices are listed in US Dollars. C4 Therapeutics employs 88 staff and has a trailing 12-month revenue of around USD$33.1 million.

How to buy shares in C4 Therapeutics

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for C4 Therapeutics. Find the stock by name or ticker symbol: CCCC. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until C4 Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of C4 Therapeutics, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of C4 Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Our top pick for

Beginners

Robinhood

Our top pick for

Building a portfolio

Sofi Invest

Our top pick for

Advanced traders

Interactive Brokers

How we chose our top picks

We evaluate stock trading platforms against a range of metrics that include fees, ease of use, available securities and advanced tools to meet specific investor needs. We encourage you to compare stock platforms to find one that's best for your particular budget and goals.

• Our pick for beginners. We chose Robinhood for this category because it offers commission-free trading and is easy to use. You can search for stocks by company name, and the mobile app is clean and intuitive to use.
• Our pick for building a portfolio. We chose SoFi for this category because it offers both commission-free stocks and a free robo-advisor. That means you can open an active investing account to pick and choose companies you want to invest in, and open a robo-advisor account to help you build a portfolio and manage how much risk you take on.
• Our pick for active traders. We picked Interactive Brokers for this category because it offers advanced tools and low fees for active investors and pros. The simpler IBKR Lite platform is aimed at less-active investors, but all users older than 21 must meet a $20,000 liquid net worth requirement for a cash account.

What's in this guide?

1. CCCC shares summary
2. Compare share dealing platforms
3. Is CCCC stock a buy or sell?
4. Stock performance over time
5. Can I short CCCC shares?
6. C4 Therapeutics's financials
7. Does C4 Therapeutics pay a dividend?
8. Other common questions

C4 Therapeutics share price

Use our graph to track the performance of CCCC stocks over time.

C4 Therapeutics shares at a glance

• Key figures

Information last updated 2021-02-24.

52-week range	USD$19 - USD$48.975
50-day moving average	USD$39.4955
200-day moving average	USD$32.6005
Wall St. target price	USD$42.67
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy C4 Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Sort by:

Name	Product	Stock trade fee	Asset types	Option trade fee	Annual fee	Signup bonus
Robinhood		$0	Stocks, Options, ETFs, Gold/Commodities	$0	0%	Free stock (chosen randomly with a value anywhere between $2.50 and $200) Sign up using the "go to site" link	Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.	Go to site More Info		loading Fetching your data...
Interactive Brokers		$0	Stocks, Bonds, Options	$0 + $0.65/contract, $1 minimum	0%	N/A	IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.	Go to site More Info		loading Fetching your data...
Tastyworks		$0	Stocks, Options, Cryptocurrency	Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg Futures: $2.50/contract to open, $0 to close	0%	Get 100 shares of stock (worth $1 to $6 a share) Open and fund a new cash or margin account with $2,000+	Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.	Go to site More Info		loading Fetching your data...
Moomoo		$0 for US stocks	Stocks, Options, ETFs	$0		N/A	Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.	Go to site More Info		loading Fetching your data...
TradeStation		$0	Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency	$0 + $0.50/contract		$50 Deposit qualifying assets of $5,000+	A platform built for all kinds of traders and all styles of trading	Go to site More Info		loading Fetching your data...

loading

Compare up to 4 providers

Clear selection

Compare

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy C4 Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of C4 Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Shorting C4 Therapeutics shares

There are currently 1.5 million C4 Therapeutics shares held short by investors – that's known as C4 Therapeutics's "short interest". This figure is 14.7% down from 1.8 million last month.

There are a few different ways that this level of interest in shorting C4 Therapeutics shares can be evaluated.

C4 Therapeutics's "short interest ratio" (SIR)

C4 Therapeutics's "short interest ratio" (SIR) is the quantity of C4 Therapeutics shares currently shorted divided by the average quantity of C4 Therapeutics shares traded daily (recently around 211824.75928473). C4 Therapeutics's SIR currently stands at 7.27. In other words for every 100,000 C4 Therapeutics shares traded daily on the market, roughly 7270 shares are currently held short.

To gain some more context, you can compare C4 Therapeutics's short interest ratio against those of similar companies.

• Regeneron Pharmaceuticals (REGN.US): 1.96
• Biogen (BIIB.US): 2.72
• Alector (ALEC.US): 10.7

However C4 Therapeutics's short interest can also be evaluated against the total number of C4 Therapeutics shares, or, against the total number of tradable C4 Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case C4 Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 C4 Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.0487% of the tradable shares (for every 100,000 tradable C4 Therapeutics shares, roughly 49 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against C4 Therapeutics.

Find out more about how you can short C4 Therapeutics stock.

C4 Therapeutics overview

C4 Therapeutics, Inc., a biopharmaceutical company, develops novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable degrader targeting IKZF1/3 for multiple myeloma, peripheral T-cell lymphoma, and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid malignancies; and BRAF V600E and RET programs for genetically defined resistant solid tumors. It has strategic collaborations with F. Hoffman-La Roche Ltd.; Biogen, Inc.; and Calico Life Sciences LLC. C4 Therapeutics, Inc. was founded in 2015 and is headquartered in Watertown, Massachusetts.

Frequently asked questions

• What percentage of C4 Therapeutics is owned by insiders or institutions?

  Currently 13.248% of C4 Therapeutics shares are held by insiders and 36.565% by institutions.

• How many people work for C4 Therapeutics?

  Latest data suggests 88 work at C4 Therapeutics.

• When does the fiscal year end for C4 Therapeutics?

  C4 Therapeutics's fiscal year ends in December.

• Where is C4 Therapeutics based?

  C4 Therapeutics's address is: 490 Arsenal Way, Watertown, MA, United States, 02472

• What is C4 Therapeutics's ISIN number?

  C4 Therapeutics's international securities identification number is: US12529R1077